Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab

Mario Cazzola, Maria Gabriella Matera, Francesca Levi-Schaffer, Paola Rogliani

Research output: Contribution to journalArticle

Abstract

Introduction: Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of exacerbations despite receiving their current asthma medicines. Areas covered: Current literature on reslizumab has been reviewed with a specific focus on its safety profile in the treatment of severe asthma. Expert opinion: Large pivotal and supportive trials reinforce the view that reslizumab is well tolerated, with an acceptable safety profile in patients exposed for longer than 2 years. However, no or few data concerning safety in special populations such as smokers, those with immune- and cellular senescence, patients with comorbidities and those receiving multi-drug treatments are available as yet. Furthermore, we need to fully elucidate some fundamental issues such as the risk of anaphylaxis and the long-term risk-benefit ratio of the impact of depletion of eosinophils and the potential risk of malignancies induced by a treatment with this anti-IL-5 agent.

Original languageEnglish
Pages (from-to)429-435
Number of pages7
JournalExpert Opinion on Drug Safety
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 3 2018

Keywords

  • Asthma
  • eosinophils
  • interleukin-5
  • monoclonal antibodies
  • reslizumab
  • safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab'. Together they form a unique fingerprint.

  • Cite this